Table A3.3

Sensitivities and specificities of FNA for early breast cancer patients having suspected lymph nodes with US: individual studies and pooled estimates

SensitivitySpecificity
Meanse95% CIMeanse95% CI
Bedrosian0.25000.03000.05490.57191-0.69151
Brancato0.68330.03690.55040.79741-0.94221
Damera0.77140.03260.59860.89581-0.82351
Deurloo0.75510.02630.61130.86661-0.80491
Podkrajsek0.84210.02840.68750.93980.90910.02240.58720.9977
Total0.72160.03220.65860.78470.99160.00840.97521
Excluding Bedrosian0.75270.03200.69010.81540.99080.00910.97291
Excluding Brancato0.73880.03790.66440.81320.98250.01740.94841
Excluding Bedrosian and Brancato0.78690.03710.71420.85960.97870.02100.93751

se = standard error; 95% CI = 95% confidence interval

From: Appendix 3, A cost effectiveness analysis of pretreatment ultrasound for the staging of the axilla in early breast cancer patients

Cover of Early and Locally Advanced Breast Cancer
Early and Locally Advanced Breast Cancer: Diagnosis and Treatment [Internet].
NICE Clinical Guidelines, No. 80.
National Collaborating Centre for Cancer (UK).
Copyright © 2009, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.